NO996044L - Rapamycinformuleringer for oral administrasjon - Google Patents

Rapamycinformuleringer for oral administrasjon

Info

Publication number
NO996044L
NO996044L NO996044A NO996044A NO996044L NO 996044 L NO996044 L NO 996044L NO 996044 A NO996044 A NO 996044A NO 996044 A NO996044 A NO 996044A NO 996044 L NO996044 L NO 996044L
Authority
NO
Norway
Prior art keywords
oral administration
rapamycin formulations
rapamycin
formulations
oral
Prior art date
Application number
NO996044A
Other languages
English (en)
Other versions
NO996044D0 (no
Inventor
Arwinder Singh Nagi
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of NO996044D0 publication Critical patent/NO996044D0/no
Publication of NO996044L publication Critical patent/NO996044L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
NO996044A 1997-06-13 1999-12-08 Rapamycinformuleringer for oral administrasjon NO996044L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87496597A 1997-06-13 1997-06-13
PCT/US1998/012142 WO1998056358A1 (en) 1997-06-13 1998-06-11 Rapamycin formulations for oral administration

Publications (2)

Publication Number Publication Date
NO996044D0 NO996044D0 (no) 1999-12-08
NO996044L true NO996044L (no) 1999-12-08

Family

ID=25364977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996044A NO996044L (no) 1997-06-13 1999-12-08 Rapamycinformuleringer for oral administrasjon

Country Status (26)

Country Link
EP (1) EP0994697B1 (no)
JP (1) JP2002504124A (no)
KR (1) KR20010013650A (no)
CN (1) CN1133424C (no)
AR (1) AR012971A1 (no)
AT (1) ATE283687T1 (no)
AU (1) AU743584B2 (no)
BR (1) BR9810746A (no)
CA (1) CA2293793C (no)
CZ (1) CZ295276B6 (no)
DE (1) DE69827947T2 (no)
DK (1) DK0994697T3 (no)
ES (1) ES2232948T3 (no)
HU (1) HUP0003341A3 (no)
IL (1) IL132986A0 (no)
NO (1) NO996044L (no)
NZ (1) NZ501652A (no)
PL (1) PL337320A1 (no)
PT (1) PT994697E (no)
RU (1) RU2184541C2 (no)
SK (1) SK284472B6 (no)
TR (1) TR199903065T2 (no)
TW (1) TW574040B (no)
UA (1) UA65573C2 (no)
WO (1) WO1998056358A1 (no)
ZA (1) ZA985095B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP4969747B2 (ja) * 2001-01-19 2012-07-04 武田薬品工業株式会社 錠剤フィルムコーティング用組成物
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
ES2485841T3 (es) 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compuestos que contienen fósforo y usos de los mismos
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
CN102138903B (zh) * 2011-03-17 2012-12-12 苏州特瑞药业有限公司 一种依维莫司固体口服药物组合物
CN110585159B (zh) * 2019-09-12 2021-11-02 杭州华东医药集团新药研究院有限公司 一种含有西罗莫司的片剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525960B1 (en) * 1991-06-18 1996-03-20 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration

Also Published As

Publication number Publication date
HUP0003341A3 (en) 2001-03-28
RU2184541C2 (ru) 2002-07-10
EP0994697A1 (en) 2000-04-26
DE69827947T2 (de) 2005-04-21
ES2232948T3 (es) 2005-06-01
UA65573C2 (uk) 2004-04-15
AU743584B2 (en) 2002-01-31
CZ450299A3 (cs) 2000-08-16
KR20010013650A (ko) 2001-02-26
SK284472B6 (sk) 2005-04-01
PT994697E (pt) 2005-02-28
BR9810746A (pt) 2000-09-19
NO996044D0 (no) 1999-12-08
AR012971A1 (es) 2000-11-22
TW574040B (en) 2004-02-01
CN1133424C (zh) 2004-01-07
PL337320A1 (en) 2000-08-14
IL132986A0 (en) 2001-03-19
DE69827947D1 (de) 2005-01-05
ATE283687T1 (de) 2004-12-15
SK171799A3 (en) 2000-07-11
DK0994697T3 (da) 2005-02-14
NZ501652A (en) 2001-09-28
CN1259864A (zh) 2000-07-12
CZ295276B6 (cs) 2005-06-15
ZA985095B (en) 1999-12-13
JP2002504124A (ja) 2002-02-05
HUP0003341A2 (hu) 2001-02-28
CA2293793A1 (en) 1998-12-17
CA2293793C (en) 2006-07-11
EP0994697B1 (en) 2004-12-01
TR199903065T2 (xx) 2000-09-21
WO1998056358A1 (en) 1998-12-17
AU7836898A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ID23299A (id) Formulasi-formulasi farmasi
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
ID24654A (id) Formulasi farmasi omeprazola
EE04901B1 (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
NO993096D0 (no) Orale cyklosporinformuleringer
DK0907364T3 (da) Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
NO20015670L (no) Forbedrede farmasöytiske formuleringer
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
DE69807768T2 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung
DE69632125D1 (de) Orale cyclosporinformulierungen
FI944534A (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
ID16781A (id) Formulasi-formulasi farmasi
NO996044L (no) Rapamycinformuleringer for oral administrasjon
ATE295150T1 (de) Pharmazeutische zusammensetzungen
ID30032A (id) Formulasi farmasi
NO20003284D0 (no) Farmasøytisk preparat for oral administrering
SE9502453D0 (sv) Drug formulations
SE9404467D0 (sv) Drug formulations
SE9803952D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application